AstraZeneca has licensed a Generation 2.5 antisense drug—a form of treatment for genetic...
- BenevolentAI buys research facility to support drug development
- AstraZeneca buys licence to antisense drug for up to $330 million
- AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
- Will Amazon be the new face of healthcare?
- Takeda and Wave Life Sciences to develop neurological treatments
BenevolentAI buys research facility to support drug development
British artificial intelligence (AI) company BenevolentAI has purchased a drug discovery and development facility located on the Babraham Research Campus in Cambridge, UK, to bolster its AI-enabled development of medicines.
AstraZeneca buys licence to antisense drug for up to $330 million
AstraZeneca has licensed a Generation 2.5 antisense drug—a form of treatment for genetic disorders—t o treat kidney disease from Ionis Pharmaceuticals for up to $330 million.
AAD 2018: strong Phase IIb results for upadacitinib in atopic dermatitis
On 17 February, primary results from a Phase IIb clinical trial assessing the use of AbbVie’s upadacitinib in adult patients with moderate to severe atopic dermatitis (AD) was presented at the 76th Annual American Academy of Dermatology (AAD) meeting.
Takeda and Wave Life Sciences to develop neurological treatments
Takeda Pharmaceutical has signed a research, development and commercial collaboration and multi-programme option agreement with Wave Life Sciences to create new antisense oligonucleotides as treatments for genetically defined neurological diseases.
Charles Ischi Presents Modular Tablet Hardness Tester LAB.line P-Series
Charles Ischi’s versatile laboratory tablet hardness testers in the P-Series offer you the latest technology, space-saving design and maximum flexibility.
Fast Trak Services: A collaborative Project to Accelerate Downstream Biosimilar Process Development
Biosimilars represent an innovative solution to benefit both patients and healthcare systems by reducing the burden of rising treatment costs.
The ophthalmology biosimilars market is still in its infancy
2017 has proved to be a remarkable year for biosimilars in ophthalmology, with the EMA approval of Amgen’s Amgevita in March 2017, followed by Biogen/Samsung Bioepis’s Imraldi in August and BI’s Cyltezo in November.
AAD 2018: Is Tremfya more cost-effective than Cosentyx and Taltz?
At the 76th annual meeting of the American Academy of Dermatology, Johnson & Johnson (J&J) released a cost per responder analysis of their interleukin 23 subunit alpha (IL-23A) inhibitor Tremfya (guselkumab) compared with Novartis’ IL-17 inhibitor Cosentyx (secukinumab) and Eli Lilly’s IL-17A inhibitor Taltz (ixekizumab) for the treatment of moderate to severe plaque psoriasis (PsO).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.